Fundacion Seimc Gesida

3 trials Academic / non-commercial

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

4 Completed trials

1 Countries active

10 Unique IMPs

100% Results reported

Phase III/IV

Phase IV

Phase III/IV: 1 Phase IV: 2

Oversight events:

4 serious breaches across 1 trial

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR 2 LAMIVUDINE, DOLUTEGRAVIR SODIUM 2 DOLUTEGRAVIR SODIUM 1 DOLUTEGRAVIR SODIUM, RILPIVIRINE HYDROCHLORIDE 1 EMTRICITABINE, TENOFOVIR ALAFENAMIDE 1 EMTRICITABINE, TENOFOVIR ALAFENAMIDE, RILPIVIRINE 1 EMTRICITABINE, TENOFOVIR DISOPROXIL 1 EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE 1 EMTRICITABINE, TENOFOVIR DISOPROXIL, RILPIVIRINE 1 RILPIVIRINE 1

All trials

3 total

Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment… Ended

2022-503110-23-00 Phase IV 1 country DOLUTEGRAVIR SODIUM; DOLUTEGRAVIR SODIUM, RILPIVIRINE HYDROCHLORIDE; EMTRICITABI…
Clinical Trial to Evaluate the Safety and Appropriateness of Switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir A… Ended

2024-511951-16-00 Phase IV 1 country EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; LAMIVUDINE, DOLUTEGRAVIR SODI…
DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial Ended

2024-515167-56-00 Phase III/IV 1 country EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; LAMIVUDINE, DOLUTEGRAVIR SODI…

Showing 1–3 of 3 trials

← All sponsors A–Z